Eisai

News

A settlement between Eisai and Torrent Pharma will keep a generic version of blockbuster cancer drug Lenvima off the US market until 2030.

News

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.

News

Before it has even launched, Eisai has filed to widen subcutaneous Leqembi's label to include starting as well as maintenance dosing in Alzheimer's.

News

Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?

News

Germany and Austria are the first countries in the EU to see the launch of Leqembi, Eisai and Biogen's much-delayed treatment for Alzheimer's.

Oncology

Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, discusses the data Eisai presented at ASCO 2025.